Dupilumab shows significant and sustained improvements in children with severe atopic dermatitis

The efficacy of dupilumab in improving atopic dermatitis (AD) signs, symptoms, and quality of life (QoL) in children aged 6-11 years with severe AD was demonstrated in a post hoc analysis of a Phase 3 clinical trial.

The trial, which involved 304 patients receiving either dupilumab or placebo along with concomitant topical corticosteroids (TCS), evaluated the percentage of patients deemed responsive to dupilumab treatment at week 16.

The results showed that nearly all patients receiving dupilumab with TCS (95%) demonstrated clinically meaningful improvements in AD signs, symptoms, or QoL, in contrast to only 61% of patients in the placebo group with TCS.

The improvements were observed as early as week 2 and were sustained throughout the duration of the study in both the full analysis set and the subgroup of patients who had an Investigator’s Global Assessment score >1 at week 16.

Reference
Siegfried EC, Cork MJ, Katoh N, et al. Dupilumab Provides Clinically Meaningful Responses in Children Aged 6-11 Years with Severe Atopic Dermatitis: Post Hoc Analysis Results from a Phase III Trial. Am J Clin Dermatol. 2023;doi: 10.1007/s40257-023-00791-7. Epub ahead of print. PMID: 37300760.